GHK-Cu vs Epithalon
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, an endogenous human plasma tripeptide studied since the 1980s for collagen synthesis, extracellular-matrix remodelling and wound repair. Epithalon, also written Epitalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly derived from the pineal extract preparation Epithalamin, and its literature reports telomerase induction, circadian and pineal gene expression and lifespan extension in Drosophila and rodents. The pair is compared because both are sold as anti-ageing peptides, but they were developed in different research traditions, target different biology and rest on evidence bases that differ in independence as much as in size. No study has administered both, in any species or model. Two 2026 reviews, one in gerontology and one in orthopaedics, describe them side by side without comparing them, and those two papers are the whole of the literature that engages the pair.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published experiment has tested GHK-Cu and Epithalon together or against each other, and searches of PubMed and Europe PMC across peptide names, sequence names and the Epithalamin preparation returned no comparative study. Both appear together only in review articles. A 2026 review of therapeutic peptides in gerontology selected nine peptides spanning different hallmarks of ageing and assigned Epitalon to telomere biology and GHK-Cu to dermal regeneration, reporting that the non-approved peptides it covered showed promising preclinical and limited clinical evidence while lacking long-term safety data and systematic validation. A 2026 review of therapeutic peptides in orthopaedics placed GHK-Cu among wound-healing peptides, attributing collagen turnover, antioxidant defence and matrix regeneration to it, and placed epithalon among recovery-enhancing agents said to act on circadian and mitochondrial regulators, while stating that clinical trials were lacking across the peptides reviewed. Neither review generated comparative data, so every difference between the two rests on separate studies in different models, species and decades.
The 2 publications that cover both
- 01Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, et al. · Front Aging · narrative review with systematic searches of PubMed, Scopus and FDA and WADA databases from inception through January 2026; nine peptides identified, including epitalon and GHK-Cu, from 20 selected primary sources
The review assigned Epitalon to telomere biology, describing activation of telomerase, telomere lengthening and modulation of pineal function, and assigned GHK-Cu to dermal regeneration. It reported that the FDA-approved agents it covered had robust safety profiles from large-scale trials, while the non-approved peptides, both of these among them, showed promising preclinical and limited clinical evidence but lacked long-term safety data and systematic validation. Dosing regimens, combination effects and monitoring biomarkers were named as knowledge gaps.
- 02Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, et al. · J Am Acad Orthop Surg Glob Res Rev · narrative review of therapeutic peptides in orthopaedic injury management, grouped into wound-healing peptides, growth hormone secretagogues, recovery-enhancing agents and neuroactive peptides
The review grouped GHK-Cu with BPC-157 and TB-500 as wound-healing peptides, attributing collagen turnover, antioxidant defence, matrix regeneration, matrix metalloproteinase regulation and copper-redox activity to it. Epithalon was grouped with delta sleep-inducing peptide and pinealon as recovery-enhancing agents described as targeting circadian and mitochondrial regulators. The authors stated that preclinical studies were promising but that clinical trials were lacking across the peptides reviewed.
Side by side.
| GHK-Cu | Epithalon | |
|---|---|---|
| Evidence maturity | Early clinical | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 10 | 8 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | Glycyl-L-histidyl-L-lysine complexed with copper(II), an endogenous human plasma tripeptide that binds copper with high affinity and was first characterised in the 1970s and 1980s. | The synthetic tetrapeptide Ala-Glu-Asp-Gly, derived from the pineal gland extract preparation Epithalamin and developed in the Russian peptide-bioregulator tradition. |
| Mechanism as described in the literature | Copper binding and transport, stimulation of collagen and glycosaminoglycan synthesis in cultured fibroblasts, and gene-expression work reporting broad modulation of extracellular-matrix, antioxidant and inflammatory programmes. | Induction of telomerase activity and telomere elongation in cultured human cells, modulation of circadian and pineal gene expression, antioxidant effects and reported epigenetic chromatin modification. |
| Size of the evidence base | Fifteen studies in this library: six human clinical, one systematic review, four in vitro, two animal in vivo and two reviews, spanning 1988 to 2026. | Fifteen studies: eight in vitro, three animal in vivo, two human clinical and two reviews, spanning 2000 to 2026. |
| Human data | Controlled human trials exist but are few and inconsistent. The two largest randomised trials of topical copper tripeptide, in venous stasis ulcers and after CO2 laser resurfacing, found no significant benefit on their objective endpoints, and a 2026 systematic review located only two randomised controlled trials of GHK-Cu as a standalone aesthetic intervention. | No registered, placebo-controlled randomised trial of the synthetic tetrapeptide has been published. The human longevity reports used the pineal extract preparation Epithalamin under non-randomised open designs, and the most recent human work sampled buccal epithelial cells rather than testing a clinical endpoint. |
| Independence of the literature | Distributed across independent groups and journals over several decades, including cosmetic science, dermatology, respiratory medicine and model-organism biology. | Dominated by a single research group, the St Petersburg Institute of Bioregulation and Gerontology, with much of the output in Russian-language journals; the small number of independent replications published between 2022 and 2025 are in vitro only. |
| Best-characterised finding | Stimulation of collagen synthesis in cultured fibroblasts across a picomolar to nanomolar dose-response, reported in 1988. | Induction of telomerase activity and telomere elongation in human fetal fibroblasts at the Hayflick limit, reported in 2003 and revisited by independent in vitro work in 2025. |
| Safety questions left open | Skin permeation from cosmetic vehicles is not well characterised, and no dose-response for a topical anti-wrinkle effect has been established in humans, so the exposure achieved in cosmetic use is unknown. | Human pharmacokinetics, dose-response and long-term safety are uncharacterised, and any oncological risk arising from telomerase induction has not been addressed in a published human study. |
| Regulatory status | No approved medicine. GHK-Cu is used as a cosmetic ingredient, and the 2026 systematic review of its aesthetic use classified most of the supporting literature as preclinical. | No approved medicine and no registered trial in the indexed literature; the 2026 gerontology review that covered it recorded the absence of long-term safety data and systematic validation. |
And what it does not.
These two peptides are compared because they share a shelf, not because any study has weighed them against each other. GHK-Cu has the older and more independent record: decades of in vitro and animal work in skin, a small number of controlled human trials whose largest examples were negative, and a 2026 systematic review that found only two randomised trials of the peptide used on its own. Epithalon has a striking preclinical claim, telomerase induction and telomere elongation in human cells, together with lifespan data in flies and rodents, but its literature originates overwhelmingly from one institute, its human reports used a pineal extract rather than the synthetic tetrapeptide, and no registered randomised trial has been published. Neither has established human pharmacokinetics for the way it is sold, and the reviews that name both place them together among unapproved peptides with promising preclinical data and insufficient clinical validation.
Common questions.
- Has any experiment tested GHK-Cu and Epithalon in the same model?
No. Searches of PubMed and Europe PMC using peptide names, sequence names and the Epithalamin preparation returned no study containing arms for both, in cell culture, in animals or in humans. The two publications that name both are 2026 review articles, one in gerontology and one in orthopaedics, which assign each peptide to a different category and describe them separately. No measured comparison of potency, exposure or outcome between the two exists.
- What did the 2026 gerontology review conclude about both peptides?
It selected nine peptides spanning different hallmarks of ageing, placing Epitalon under telomere biology and GHK-Cu under dermal regeneration. For the approved agents it covered, it recorded robust safety profiles from large-scale trials. For the non-approved peptides, both of these included, it reported promising preclinical and limited clinical evidence alongside an absence of long-term safety data and systematic validation, and named dosing regimens, combination effects and monitoring biomarkers as unresolved gaps.
- Which of the two has randomised controlled human evidence?
Only GHK-Cu, and the results are unfavourable. A 1992 prospective randomised evaluator-blinded trial in venous stasis ulcers and a 2006 randomised trial after CO2 laser resurfacing both tested topical copper tripeptide and found no significant benefit on their objective endpoints. Epithalon has no published registered randomised placebo-controlled trial; the human longevity reports associated with it used the pineal extract Epithalamin under non-randomised open designs.
- Do the two peptides address the same biology of ageing?
The published mechanisms do not overlap. GHK-Cu work concerns copper binding, collagen and glycosaminoglycan synthesis and extracellular-matrix remodelling, largely in skin. Epithalon work concerns telomerase activity, telomere length, pineal and circadian gene expression and antioxidant effects. Reviews that cover both assign them to separate categories for that reason, and no study has measured one peptide against an endpoint characteristic of the other.
- What remains uncharacterised for each peptide in humans?
For GHK-Cu, skin permeation from cosmetic vehicles is not well described and no dose-response for a topical anti-wrinkle effect has been established, so the exposure achieved in ordinary use is unknown. For Epithalon, human pharmacokinetics, dose-response and long-term safety are unpublished, and the oncological question raised by telomerase induction has not been examined in any human study. Neither peptide has an approved indication in any jurisdiction.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.